Clinical trials: Moderate Plaque Psoriasis
Psoriasis, Plaque Type Psorisis
Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204.
- Conditions
- Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
- Trial name
- NCT06723171
- Testing
- IRX4204
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Io Therapeutics
Chronic Plaque Psoriasis
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.
- Trial name
- NCT02969018
- Testing
- PF-06700841
- Where
- 44 sites in United States, Canada and 1 more
- Volunteers
- 212 people
- Sponsor
- Pfizer
Psoriasis
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.
- Trial name
- NCT01543204
- Testing
- Etanercept
- Where
- 47 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Amgen
Plaque Psoriasis
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06176768
- Testing
- LY3972406
- Where
- 12 sites in United States
- Volunteers
- 33 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis
This is a Phase Ib clinical study of multiple dose escalation of AK111 in subjects with moderate-to-severe plaque psoriasis
- Trial name
- NCT05504317
- Testing
- AK111
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Akeso
Parapsoriasis
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo…
- Trial name
- UNVEIL (NCT02425826)
- Testing
- Apremilast
- Where
- 26 sites in United States
- Volunteers
- 221 people
- Sponsor
- Amgen
Moderate to Severe Chronic Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of JS005 in 702 adult patients with moderate-to-severe chronic plaque psoriasis
- Trial name
- NCT05975268
- Testing
- JS005 (recombinant humanized monoclonal antibody against IL-17A)
- Where
- 63 sites in China
- Volunteers
- 747 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- SUMMIT (NCT05357755)
- Testing
- JNJ-77242113
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.
- Trial name
- UNCOVER-A (NCT01777191)
- Testing
- Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Plaque Psoriasis Study in Pediatric Subjects
The purpose of this study is to compare the safety, efficacy and calcium metabolism of up to 8 weeks of treatment with calcitriol 3 mcg/g ointment versus its vehicle, when used twice daily, without occlusion, to treat children…
- Trial name
- NCT02186665
- Testing
- calcitriol ointment
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 19 people
- Sponsor
- Galderma R&D
Psoriasis
Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
The purpose of this study is to determine whether Cloderm Cream is effective for topical treatment of moderate psoriasis over 28 days.
- Trial name
- NCT01714544
- Testing
- Cloderm Cream
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Promius Pharma, LLC
Psoriasis
A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis
Psoriasis is a common, chronic skin disease for which only remissive, as opposed to curative, treatments are available. Traditional Chinese medicine is one of the most frequently chosen alternative therapies in China and Taiwan…
- Trial name
- NCT01901705
- Testing
- Indigo naturalis ointment
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- China Medical University Hospital
Psoriasis
Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）
This is a multicenter, one-arm, prospective, observational study，intended to assess evaluation of efficacy and safety of Apremilast in Chinese patients with moderate-to-severe plaque psoriasis。During this study, it is expected to…
- Trial name
- NCT05863273
- Testing
- Apremilast
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- First Hospital of China Medical University
Plaque Psoriasis, Psoriasis (PsO)
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: How safe is taking ESK-001 long-term in people with moderate to…
- Conditions
- Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
- Trial name
- ONWARD3 (NCT06846541)
- Testing
- Open-Label Envudeucitinib, Blinded Envudeucitinib
- Where
- 268 sites in United States, Australia and 14 more
- Volunteers
- 1,680 people
- Sponsor
- Alumis Inc
Chronic Plaque Psoriasis
Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis
It is a phase IV multicentric, placebo-controlled, clinical trial investigating the efficacy and safety of acitretin combined to efalizumab in the therapy of chronic plaque psoriasis.
- Trial name
- CobAcE (NCT00707070)
- Testing
- efalizumab plus acitretin
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universita di Verona
Psoriasis
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206660
- Testing
- Desoximetasone Spray 0.25%
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Plaque Psoriasis
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospitals in Turkey.
- Trial name
- NCT05344482
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE VIVID (NCT03370133)
- Testing
- Bimekizumab, Ustekinumab
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 567 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT05600036
- Testing
- ESK-001
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 228 people
- Sponsor
- Alumis Inc
Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT02 (Alvotech Biosimilar to Adalimumab), in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT03849404
- Testing
- Adalimumab
- Where
- 20 sites in Estonia, Georgia and 2 more
- Volunteers
- 413 people
- Sponsor
- Alvotech Swiss AG